Last reviewed · How we verify
Metformin and insulin
Metformin reduces hepatic glucose production and improves insulin sensitivity, while insulin directly replaces or supplements endogenous insulin to lower blood glucose.
Metformin reduces hepatic glucose production and improves insulin sensitivity, while insulin directly replaces or supplements endogenous insulin to lower blood glucose. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Metformin and insulin |
|---|---|
| Sponsor | Takeda |
| Drug class | Antidiabetic combination (biguanide + insulin) |
| Target | Metformin: AMP-activated protein kinase (AMPK) pathway; Insulin: insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Metformin is a biguanide that decreases gluconeogenesis and glycogenolysis in the liver and increases peripheral glucose uptake and utilization. Insulin is a hormone that facilitates glucose uptake into cells and promotes anabolic metabolism. The combination addresses both insulin resistance (metformin) and absolute or relative insulin deficiency (insulin) in diabetes management.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Gastrointestinal disturbance (metformin component)
- Weight gain
- Injection site reactions
Key clinical trials
- Surgical or Medical Treatment (PHASE4)
- Effect of Short-Term Beta-Cell Rest in Adolescents and Young Adults With Type 2 Diabetes Mellitus
- Effects of Cofrogliptin on Beta-Cell Function in LADA Patients (NA)
- The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity (PHASE4)
- Effect of Pioglitazone vs Metformin on Clinical, Biochemical and Hormonal Parameters of Insulin Resistant PCOS (NA)
- Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease (PHASE2)
- A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes (PHASE3)
- Focusing on the Menopausal Transition to Improve Mid-Life Women's Health (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metformin and insulin CI brief — competitive landscape report
- Metformin and insulin updates RSS · CI watch RSS
- Takeda portfolio CI